The promise and peril of KRAS G12C inhibitors

RAS mutant tumors have been largely refractory to therapies until now. Recent findings published in the New England Journal of Medicine show that sotorasib provides clinical benefit for KRAS p.G12C-mutated non-small-cell lung cancer (NSCLC) and provide mechanistic insights into acquired resistance to KRAS(G12C)-specific inhibition.

Automated summary

The study found that sotorasib provides clinical benefit for KRAS p.G12C-mutated non-small-cell lung cancer (NSCLC) and provides mechanistic insights into acquired resistance to KRAS(G12C)-specific inhibition.